A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer.
- DOI
- 10.3389/fimmu.2026.1839684
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1839684,
title = {A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer.},
author = {Zhou D and Ran B and Kong L and Liu Y and Xiao L and Chen X and Liu W and Li X and Zhang J and Zhang J and Wu H and Zhang G and Gu X and Zhang W and Wu J and Jiang C},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1839684},
url = {https://doi.org/10.3389/fimmu.2026.1839684}
}RIS
TY - JOUR TI - A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer. AU - Zhou D AU - Ran B AU - Kong L AU - Liu Y AU - Xiao L AU - Chen X AU - Liu W AU - Li X AU - Zhang J AU - Zhang J AU - Wu H AU - Zhang G AU - Gu X AU - Zhang W AU - Wu J AU - Jiang C PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1839684 UR - https://doi.org/10.3389/fimmu.2026.1839684 ER -
APA
D, Z., B, R., L, K., Y, L., L, X., X, C., W, L., X, L., J, Z., J, Z., H, W., G, Z., X, G., W, Z., J, W., & C, J. (2026). A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1839684
Source records
- pubmed · retrieved 2026-09-27T01:29:28.299Z
- europe-pmc · retrieved 2026-09-27T01:29:28.306Z
- doaj · retrieved 2026-09-27T01:29:28.301Z